Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Descriptor ID |
D016403
|
| MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
| Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Lymphoma, Large-Cell, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in this website by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 6 | 8 |
| 1995 | 5 | 1 | 6 |
| 1996 | 7 | 4 | 11 |
| 1997 | 5 | 6 | 11 |
| 1998 | 6 | 0 | 6 |
| 1999 | 5 | 0 | 5 |
| 2000 | 8 | 1 | 9 |
| 2001 | 10 | 2 | 12 |
| 2002 | 11 | 5 | 16 |
| 2003 | 12 | 0 | 12 |
| 2004 | 8 | 3 | 11 |
| 2005 | 8 | 0 | 8 |
| 2006 | 13 | 5 | 18 |
| 2007 | 13 | 0 | 13 |
| 2008 | 11 | 3 | 14 |
| 2009 | 10 | 1 | 11 |
| 2010 | 23 | 1 | 24 |
| 2011 | 17 | 2 | 19 |
| 2012 | 17 | 1 | 18 |
| 2013 | 28 | 1 | 29 |
| 2014 | 26 | 1 | 27 |
| 2015 | 39 | 5 | 44 |
| 2016 | 38 | 4 | 42 |
| 2017 | 26 | 4 | 30 |
| 2018 | 26 | 2 | 28 |
| 2019 | 26 | 0 | 26 |
| 2020 | 36 | 1 | 37 |
| 2021 | 47 | 1 | 48 |
| 2022 | 47 | 0 | 47 |
| 2023 | 42 | 0 | 42 |
| 2024 | 24 | 2 | 26 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL. Blood Adv. 2024 08 27; 8(16):4414-4422.
-
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Nov; 30(11):1065-1079.
-
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
-
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024 Oct 20; 42(30):3581-3592.
-
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
-
Defining primary refractory large B-cell lymphoma. Blood Adv. 2024 07 09; 8(13):3402-3415.
-
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 07 08; 14(1):108.
-
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct; 99(10):2002-2015.
-
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024 06 27; 143(26):2722-2734.
-
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv. 2024 06 11; 8(11):2982-2990.